Cogent Biosciences
COGT
161 hedge funds and large institutions have $1.32B invested in Cogent Biosciences in 2024 Q3 according to their latest regulatory filings, with 31 funds opening new positions, 54 increasing their positions, 47 reducing their positions, and 18 closing their positions.
72% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 18
29% more capital invested
Capital invested by funds: $1.02B → $1.32B (+$293M)
17% more funds holding in top 10
Funds holding in top 10: 6 → 7 (+1)
15% more repeat investments, than reductions
Existing positions increased: 54 | Existing positions reduced: 47
9% more funds holding
Funds holding: 148 → 161 (+13)
7% more call options, than puts
Call options by funds: $1.06M | Put options by funds: $993K
15.64% less ownership
Funds ownership: 126.96% → 111.31% (-16%)
Top Buyers
| 1 |
LGM
Logos Global Management
San Francisco,
California
|
+$19.5M |
| 2 |
OCA
Octagon Capital Advisors
New York
|
+$12.7M |
| 3 |
PBA
Paradigm Biocapital Advisors
New York
|
+$9.59M |
| 4 |
BlackRock
New York
|
+$6.85M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$6.09M |
Top Sellers
| 1 |
CC
Commodore Capital
New York
|
-$21.4M |
| 2 |
VC
Vivo Capital
Palo Alto,
California
|
-$10.9M |
| 3 |
RAM
Readystate Asset Management
Chicago,
Illinois
|
-$6.19M |
| 4 |
State Street
Boston,
Massachusetts
|
-$5.9M |
| 5 |
SI
Sofinnova Investments
Menlo Park,
California
|
-$4.95M |
COGT Hedge Fund Activity: Q3 2024 in Review
161 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Cogent Biosciences (COGT) for Q3 2024, worth a combined $1.32B — up 29% from $1.02B a quarter earlier.
Buyers outnumbered sellers: 31 funds opened new COGT positions and 18 closed out — a net gain of 13 holders — while 54 added to existing stakes and 47 trimmed.
The largest buyer was Logos Global Management, opening a new position worth an estimated $19.5M. The largest seller was Commodore Capital, cutting an estimated $21.4M.
- 161 institutional investors held Cogent Biosciences (COGT) as of Q3 2024, up from 148 in Q2 2024.
- Funds reported $1.32B of Cogent Biosciences stock for Q3 2024, up 29% quarter-over-quarter.
- 31 funds opened new Cogent Biosciences positions in Q3 2024 and 18 closed out, a net change of +13 holders.
- The largest Cogent Biosciences buyer in Q3 2024 was Logos Global Management, an estimated $19.5M added.
- The largest Cogent Biosciences seller in Q3 2024 was Commodore Capital, an estimated $21.4M sold.
Based on aggregated 13F filings for Q3 2024.